Valuation: OneSource Specialty Pharma Limited

Market Cap 182B 1.89B 1.67B 1.58B 1.43B 2.69B 2.71B 18.95B 7.3B 92.69B 7.1B 6.95B 298B P/E 2027 *
39.1x
P/E 2028 * 18.9x
Enterprise Value 190B 1.98B 1.75B 1.66B 1.5B 2.82B 2.84B 19.87B 7.66B 97.21B 7.45B 7.29B 313B EV / Sales 2027 *
8.73x
EV / Sales 2028 * 5.37x
Free-Float
64.51%
Yield 2027 *
-
Yield 2028 * -
1 day+1.12%
1 week-0.29%
Current month+4.23%
1 month+3.34%
3 months-0.96%
6 months+9.41%
Current year-12.55%
1 week 1,560
Extreme 1560
1,634.4
1 month 1,504.1
Extreme 1504.1
1,657.5
Current year 1,057
Extreme 1057
1,917.8
1 year 1,057
Extreme 1057
1,925
3 years 1,057
Extreme 1057
2,248
5 years 1,057
Extreme 1057
2,248
10 years 1,057
Extreme 1057
2,248
Manager TitleAgeSince
Chief Executive Officer 54 2024-02-29
Director of Finance/CFO - 2024-07-03
Compliance Officer - 2023-03-13
Director TitleAgeSince
Chairman 65 2025-09-21
Director/Board Member 54 2024-02-29
Director/Board Member 66 2025-02-26
Change 5-day change 1-year change 3-year change Capi.($)
+1.12%-0.29%-11.96% - 1.87B
-0.03%+3.77%+12.35%+37.22% 49.06B
-0.73%-0.41%+48.84%+36.72% 44.6B
+1.36%+6.03%+343.85%+638.73% 43.24B
-0.47%-0.76%+9.75%+103.07% 41.73B
+0.34%+0.22%+5.18%+47.36% 29.93B
+1.00%-1.28%+24.23%+156.93% 17.19B
-2.94%+6.98%+5.10% - 15.35B
-3.20%-3.50%+25.33%+42.43% 15.54B
-0.86%-4.00% - - 15.11B
Average -0.44%+0.81%+51.41%+151.78% 27.36B
Weighted average by Cap. -0.27%+1.77%+73.81%+166.43%

Financials

2027 *2028 *
Net sales 21.8B 227M 200M 190M 172M 323M 326M 2.28B 877M 11.13B 853M 834M 35.82B 34.02B 355M 313M 296M 268M 503M 508M 3.55B 1.37B 17.37B 1.33B 1.3B 55.9B
Net income 4.46B 46.47M 41.01M 38.8M 35.19M 65.97M 66.62M 465M 179M 2.28B 174M 171M 7.33B 8.97B 93.46M 82.48M 78.04M 70.77M 133M 134M 936M 361M 4.58B 351M 343M 14.74B
Net Debt 8.86B 92.29M 81.45M 77.06M 69.89M 131M 132M 924M 356M 4.52B 347M 339M 14.55B 1.16B 12.13M 10.71M 10.13M 9.19M 17.22M 17.39M 122M 46.83M 594M 45.55M 44.56M 1.91B
Logo OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited is an India-based Contract Development and Manufacturing Organization (CDMO). The Company offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply. The Company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It supports the development of complex biologics, including microbial and mammalian cell line biopharmaceuticals, cell and gene therapy and ribonucleic acid (RNA) products. Its integrated services offer comprehensive biologics solutions. The Company develops a variety of soft gelatin capsules including traditional and enteric softgels, vegan capsule alternatives, chewable formats and specialty dosage forms, and liposomal systems and applicaps. It also provides end-to-end development and manufacturing of sterile injectable products.
Employees
1,674
Date Price Change Volume
26-09-29 ₹1,583.30 +1.12% 463,289
26-09-28 ₹1,565.80 -2.30% 262,280
26-09-25 ₹1,602.60 +0.50% 227,395
26-09-24 ₹1,594.60 -0.13% 104,912
26-09-23 ₹1,596.70 +0.55% 158,650
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1,583.30INR
Average target price
2,056.00INR
Spread / Average Target
+29.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ONESOURCE Stock